Hansa Biopharma Valuation Multiples

Hansa Biopharma Overview

About Hansa Biopharma

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Founded

2007

HQ

Employees

148

Website

hansabiopharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $27M

EBITDA: ($54M)

EV

$341M

Valuation Multiples

Multiples.vc

Start free trial

Hansa Biopharma Financials

Hansa Biopharma reported last 12-month revenue of $27M and negative EBITDA of ($54M).

In the same LTM period, Hansa Biopharma generated $19M in gross profit, ($54M) in EBITDA losses, and had net loss of ($62M).

Hansa Biopharma P&L

In the most recent fiscal year, Hansa Biopharma reported revenue of $25M and EBITDA of ($40M).

Hansa Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Hansa Biopharma Stock Performance

Hansa Biopharma has current market cap of $315M, and enterprise value of $341M.

Hansa Biopharma's stock price is $3.16.

Hansa Biopharma Valuation Multiples

Hansa Biopharma trades at 12.8x EV/Revenue multiple, and (6.3x) EV/EBITDA.

Hansa Biopharma Financial Valuation Multiples

As of April 19, 2026, Hansa Biopharma has market cap of $315M and EV of $341M.

Equity research analysts estimate Hansa Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hansa Biopharma has a P/E ratio of (5.1x).

Hansa Biopharma Margins & Growth Rates

Hansa Biopharma's revenue in the last 12 month grew by 63%.

Hansa Biopharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.

Hansa Biopharma's rule of 40 is (162%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hansa Biopharma's rule of X is (121%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Hansa Biopharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Hansa Biopharma M&A Activity

Hansa Biopharma acquired XXX companies to date.

Last acquisition by Hansa Biopharma was on XXXXXXXX, XXXXX. Hansa Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Hansa Biopharma Investment Activity

Hansa Biopharma invested in XXX companies to date.

Hansa Biopharma made its latest investment on XXXXXXXX, XXXXX. Hansa Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).